A case of photoleukomelanoderma due to hydrochlorothiazide contained in Preminent®

Yoshitaka Nakamura; Kei Nemoto; Emi Yokoyama; Masahiko Muto

doi:10.2336/nishinihonhifu.73.482

A case of photoleukomelanoderma due to hydrochlorothiazide contained in Preminent®

Yoshitaka Nakamura, Kei Nemoto, Emi Yokoyama, Masahiko Muto

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

A 75-year-old female had been treated with Nu-Lotan® (losartanpotassium) for hypertension. One month later, her treatment was changed from Nu-Lotan® to Preminent®(losartanpotassium/hydrochlorothiazide) and she developed pruritic edematous erythema on sun-exposed areas. Three month later eruptions appeared and pigmentations and depigmentations developed on the same areas. The minimal erythema dose (MED) of UVA was decreased to 4.4 J/cm². On withdrawal of the Preminent®, the MED was normalized. We made a diagnosis of photoleukomelanoderma due to hydrochlorothiazide contained in Preminent®.

Original language	English
Pages (from-to)	482-485
Number of pages	4
Journal	Nishinihon Journal of Dermatology
Volume	73
Issue number	5
DOIs	https://doi.org/10.2336/nishinihonhifu.73.482
Publication status	Published - 2011
Externally published	Yes

ASJC Scopus subject areas

Dermatology

Access to Document

10.2336/nishinihonhifu.73.482

Fingerprint Dive into the research topics of 'A case of photoleukomelanoderma due to hydrochlorothiazide contained in Preminent®'. Together they form a unique fingerprint.

Cite this

@article{a0859c4dec714d5caa814e9fbe280b99,

title = "A case of photoleukomelanoderma due to hydrochlorothiazide contained in Preminent{\textregistered}",

abstract = "A 75-year-old female had been treated with Nu-Lotan{\textregistered} (losartanpotassium) for hypertension. One month later, her treatment was changed from Nu-Lotan{\textregistered} to Preminent{\textregistered}(losartanpotassium/hydrochlorothiazide) and she developed pruritic edematous erythema on sun-exposed areas. Three month later eruptions appeared and pigmentations and depigmentations developed on the same areas. The minimal erythema dose (MED) of UVA was decreased to 4.4 J/cm2. On withdrawal of the Preminent{\textregistered}, the MED was normalized. We made a diagnosis of photoleukomelanoderma due to hydrochlorothiazide contained in Preminent{\textregistered}.",

author = "Yoshitaka Nakamura and Kei Nemoto and Emi Yokoyama and Masahiko Muto",

year = "2011",

doi = "10.2336/nishinihonhifu.73.482",

language = "English",

volume = "73",

pages = "482--485",

journal = "Nishinihon Journal of Dermatology",

issn = "0386-9784",

publisher = "Kyushu University, Faculty of Science",

number = "5",

}

TY - JOUR

T1 - A case of photoleukomelanoderma due to hydrochlorothiazide contained in Preminent®

AU - Nakamura, Yoshitaka

AU - Nemoto, Kei

AU - Yokoyama, Emi

AU - Muto, Masahiko

PY - 2011

Y1 - 2011

N2 - A 75-year-old female had been treated with Nu-Lotan® (losartanpotassium) for hypertension. One month later, her treatment was changed from Nu-Lotan® to Preminent®(losartanpotassium/hydrochlorothiazide) and she developed pruritic edematous erythema on sun-exposed areas. Three month later eruptions appeared and pigmentations and depigmentations developed on the same areas. The minimal erythema dose (MED) of UVA was decreased to 4.4 J/cm2. On withdrawal of the Preminent®, the MED was normalized. We made a diagnosis of photoleukomelanoderma due to hydrochlorothiazide contained in Preminent®.

AB - A 75-year-old female had been treated with Nu-Lotan® (losartanpotassium) for hypertension. One month later, her treatment was changed from Nu-Lotan® to Preminent®(losartanpotassium/hydrochlorothiazide) and she developed pruritic edematous erythema on sun-exposed areas. Three month later eruptions appeared and pigmentations and depigmentations developed on the same areas. The minimal erythema dose (MED) of UVA was decreased to 4.4 J/cm2. On withdrawal of the Preminent®, the MED was normalized. We made a diagnosis of photoleukomelanoderma due to hydrochlorothiazide contained in Preminent®.

UR - http://www.scopus.com/inward/record.url?scp=84871418970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871418970&partnerID=8YFLogxK

U2 - 10.2336/nishinihonhifu.73.482

DO - 10.2336/nishinihonhifu.73.482

M3 - Article

AN - SCOPUS:84871418970

VL - 73

SP - 482

EP - 485

JO - Nishinihon Journal of Dermatology

JF - Nishinihon Journal of Dermatology

SN - 0386-9784

IS - 5

ER -